Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands
Objectives. Patients with early-stage HR+/HER2- N0 breast cancer may receive adjuvant chemotherapy in combination with surgery. However, chemotherapy does not always lead to improved survival and incurs high healthcare costs and increased adverse events. To support decision-making regarding adjuvant...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2022/5909724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473125048123392 |
|---|---|
| author | Felix E. de Jongh Reva Efe Kirsten H. Herrmann Jelle A. Spoorendonk |
| author_facet | Felix E. de Jongh Reva Efe Kirsten H. Herrmann Jelle A. Spoorendonk |
| author_sort | Felix E. de Jongh |
| collection | DOAJ |
| description | Objectives. Patients with early-stage HR+/HER2- N0 breast cancer may receive adjuvant chemotherapy in combination with surgery. However, chemotherapy does not always lead to improved survival and incurs high healthcare costs and increased adverse events. To support decision-making regarding adjuvant chemotherapy, genomic profile testing performed with tests such as the Oncotype DX® test can help healthcare practitioners decide whether chemotherapy provides any benefit to these patients. As such, a cost-consequence model was developed with the aim to estimate the economic impact of using different gene expression tests or no testing, in patients with node-negative early-stage breast cancer. Methods. A cost-consequence model was developed to estimate the economic impact of three different scenarios in the Dutch setting: (1) Oncotype DX® test, (2) MammaPrint®, and (3) and no genomic profile testing. The model included chemotherapy costs, administration costs, short- and long-term adverse event costs, productivity loss, genomic profiling testing costs, cost of cancer recurrence, and hospitalization costs. Results. A treatment paradigm with Oncotype DX resulted in average savings per patient of €6,768 vs. a paradigm with MammaPrint and €13,125 vs. a paradigm with no genomic testing. Furthermore, due to less patients receiving adjuvant chemotherapy through better targeting by the Oncotype DX test, fewer adverse events, sick days, practice visits, and hospitalizations were required compared to MammaPrint and no genomic profiling. Conclusions. Testing with Oncotype DX test in Dutch clinical practice in patients with early-stage breast cancer proved to be cost-saving versus MammaPrint and no genomic profiling tests. Introducing the Oncotype DX test to the Dutch setting will likely reduce the economic resources that are required. |
| format | Article |
| id | doaj-art-d8d1f84ff5734916988b7d1fbc5a758a |
| institution | Kabale University |
| issn | 2090-3189 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-d8d1f84ff5734916988b7d1fbc5a758a2025-08-20T03:24:16ZengWileyInternational Journal of Breast Cancer2090-31892022-01-01202210.1155/2022/5909724Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the NetherlandsFelix E. de Jongh0Reva Efe1Kirsten H. Herrmann2Jelle A. Spoorendonk3Breast Cancer Center South Holland SouthOPEN HealthExact Sciences Deutschland GmbHOPEN HealthObjectives. Patients with early-stage HR+/HER2- N0 breast cancer may receive adjuvant chemotherapy in combination with surgery. However, chemotherapy does not always lead to improved survival and incurs high healthcare costs and increased adverse events. To support decision-making regarding adjuvant chemotherapy, genomic profile testing performed with tests such as the Oncotype DX® test can help healthcare practitioners decide whether chemotherapy provides any benefit to these patients. As such, a cost-consequence model was developed with the aim to estimate the economic impact of using different gene expression tests or no testing, in patients with node-negative early-stage breast cancer. Methods. A cost-consequence model was developed to estimate the economic impact of three different scenarios in the Dutch setting: (1) Oncotype DX® test, (2) MammaPrint®, and (3) and no genomic profile testing. The model included chemotherapy costs, administration costs, short- and long-term adverse event costs, productivity loss, genomic profiling testing costs, cost of cancer recurrence, and hospitalization costs. Results. A treatment paradigm with Oncotype DX resulted in average savings per patient of €6,768 vs. a paradigm with MammaPrint and €13,125 vs. a paradigm with no genomic testing. Furthermore, due to less patients receiving adjuvant chemotherapy through better targeting by the Oncotype DX test, fewer adverse events, sick days, practice visits, and hospitalizations were required compared to MammaPrint and no genomic profiling. Conclusions. Testing with Oncotype DX test in Dutch clinical practice in patients with early-stage breast cancer proved to be cost-saving versus MammaPrint and no genomic profiling tests. Introducing the Oncotype DX test to the Dutch setting will likely reduce the economic resources that are required.http://dx.doi.org/10.1155/2022/5909724 |
| spellingShingle | Felix E. de Jongh Reva Efe Kirsten H. Herrmann Jelle A. Spoorendonk Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands International Journal of Breast Cancer |
| title | Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands |
| title_full | Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands |
| title_fullStr | Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands |
| title_full_unstemmed | Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands |
| title_short | Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands |
| title_sort | cost and clinical benefits associated with oncotype dx r test in patients with early stage hr her2 node negative breast cancer in the netherlands |
| url | http://dx.doi.org/10.1155/2022/5909724 |
| work_keys_str_mv | AT felixedejongh costandclinicalbenefitsassociatedwithoncotypedxtestinpatientswithearlystagehrher2nodenegativebreastcancerinthenetherlands AT revaefe costandclinicalbenefitsassociatedwithoncotypedxtestinpatientswithearlystagehrher2nodenegativebreastcancerinthenetherlands AT kirstenhherrmann costandclinicalbenefitsassociatedwithoncotypedxtestinpatientswithearlystagehrher2nodenegativebreastcancerinthenetherlands AT jelleaspoorendonk costandclinicalbenefitsassociatedwithoncotypedxtestinpatientswithearlystagehrher2nodenegativebreastcancerinthenetherlands |